Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05077280 · ClinicalTrials.gov registry record · Phase 2
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
A Phase 2 study of Uveal Melanoma, sponsored by California Pacific Medical Center Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05077280: Recruiting Phase 2 study of Uveal Melanoma, sponsored by California Pacific Medical Center Research Institute.
NCT05077280 is a Phase 2 study of Uveal Melanoma that is actively recruiting participants, run by California Pacific Medical Center Research Institute. The registered enrollment target is 40 participants, below the 144-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05077280, a Phase 2 study of Uveal Melanoma, is actively recruiting participants, sponsored by California Pacific Medical Center Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 2 trial of concurrent stereotactic radiation therapy (SBRT) with immunotherapy with relatlimab and nivolumab for up to two years. SBRT will be given in three doses of 15Gy each to 1-5 separate metastases. Opdualag (nivolumab 480mg and relatlimab 160mg) will be given every 4 weeks for two years
Conditions Studied
Interventions
- DRUG Immunotherapy
- RADIATION stereotactic body radiotherapy
Study Locations (1)
California
- California Pacific Medical Center Research Institute - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
What NCT05077280 shows while recruiting
NCT05077280 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 144-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Uveal Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Immunotherapy is the first listed.
NCT05077280 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05077280 about?
NCT05077280 is a clinical study titled "A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma". This is a phase 2 trial of concurrent stereotactic radiation therapy (SBRT) with immunotherapy with relatlimab and nivolumab for up to two years. SBRT will be given in three doses of 15Gy each to 1-5 separate metastases. Opdualag (nivolumab 480mg and relatlimab 160mg) will be given every 4 weeks for...
What is the current status of trial NCT05077280?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2021-09-20. Estimated completion is 2026-03.
What conditions does trial NCT05077280 study?
This clinical trial studies the following conditions: Uveal Melanoma.
What interventions are being tested in trial NCT05077280?
The interventions under investigation include: Immunotherapy (DRUG), stereotactic body radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT05077280?
This trial is sponsored by California Pacific Medical Center Research Institute, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05077280 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05077280's enrollment target sits among peer trials
40 17th of 29 higher than 12 of 29 other Uveal Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uveal Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
RECRUITING · Phase 2
-
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Adjuvant Quisinostat in High-Risk Uveal Melanoma
RECRUITING · Phase 2
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
ACTIVE NOT RECRUITING · Phase 2
-
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI